Search Result
Results for "
2 3a Inhibitors
" in MedChemExpress (MCE) Product Catalog:
6
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-106312A
-
LY122772
|
Enterovirus
|
Infection
|
Enviroxime (LY122772) is an antiviral compound that inhibits the replication of rhinoviruses and enteroviruses. Enviroxime blocks the replication of plus-strand viral RNA by targeting the viral 3A coding region. Enviroxime can be a useful tool for investigating the natural function of the 3A protein .
|
-
-
- HY-10029
-
Nutlin-3a
Maximum Cited Publications
49 Publications Verification
Rebemadlin
|
MDM-2/p53
E1/E2/E3 Enzyme
Autophagy
Apoptosis
|
Cancer
|
Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC50=90 nM). Nutlin-3a inhibits MDM2-p53 interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53 wild-type ovarian carcinomas .
|
-
-
- HY-W969907
-
|
GSK-3
|
Others
|
GSK3a-IN-38 is a groundbreaking small molecule that effectively inhibits GSK-3a activity.
|
-
-
- HY-18899
-
|
RIP kinase
|
Cancer
|
Nec-3a is a Necrostatin-3 analogue. Nec-3a is a RIP1 inhibitor (IC50: 0.44 μM). Nec-3a inhibits the autophosphorylation activity of the RIP1 kinase domain .
|
-
-
- HY-173288
-
|
Monoamine Oxidase
|
Neurological Disease
|
MAO-B-IN-40 (3a), a MAOB inhibitor (IC50 = 0.493 μM for hMAOB), demonstrates robust neuroprotective and antioxidant effect. MAO-B-IN-40 (3a) can be used in the research of Parkinson’s disease .
|
-
-
- HY-162996
-
-
-
- HY-P10802
-
|
Enterovirus
Virus Protease
|
Infection
|
ER-DRI is a potent peptide inhibitor that tagets EV-A71. ER-DRI directly bounds to 3A and specifically abrogates viral suppressor of RNAi activity, which unlocked the antiviral RNAi response that is suppressed by 3A. ER-DRI also potently inhibits another enterovirus, Coxsackievirus-A16, dependently of RNAi .
|
-
-
- HY-157537
-
-
-
- HY-172997
-
|
iGluR
|
Neurological Disease
|
GluN1/3A-IN-1 (Compound GM-10) is a GluN1/GluN3A NMDA receptor inhibitor. GluN1/3A-IN-1 exhibits potent inhibitory activity against GluN1/GluN3A (IC50 0.98 µM). GluN1/3A-IN-1 exerts its inhibitory effect by targeting the pre-M1 region and forming hydrogen bond interactions with key residues. GluN1/3A-IN-1 can be used to study GluN1/GluN3A-related neurological diseases .
|
-
-
- HY-168119
-
|
MAP4K
|
Cancer
|
HPK1-IN-53 (compund 3a) is the potent HPK1 inhibitor (IC50=48 nM) .
|
-
-
- HY-157090
-
-
-
- HY-149479
-
|
Bacterial
|
Infection
|
Quorum sensing-IN-3 (Compound 3a) is a quorum sensing inhibitor against pseudomonas aeruginosa. Quorum sensing-IN-3 inhibits biofilm formation .
|
-
-
- HY-161293
-
|
p38 MAPK
|
Cancer
|
p38-α MAPK-IN-6 (compound 3a) is a p38α mitogen-activated protein kinase inhibitor .
|
-
-
- HY-169192
-
|
FXR
|
Inflammation/Immunology
|
BAR-2227 (compound 3a) is a FXR agonist and LIFR inhibitor. BAR-2227 can be used to study liver fibrosis and inflammation .
|
-
-
- HY-163706
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-88 (compound 3a) is a potent SARS-CoV-2 inhibitor with inhibitory value of 96.00% .
|
-
-
- HY-162913
-
|
GSK-3
|
Neurological Disease
|
GSK-3β inhibitor 20 (compound 3A) is an potent inhibitor of GSK-3β with an IC50 value of 74.4 nM .
|
-
-
- HY-17464
-
-
-
- HY-151136
-
|
DNA Methyltransferase
|
Cancer
|
DY-46-2 is a high potency and selectivity novel non-nucleoside DNA methyltransferase 3A (DNMT3A) inhibitor with an IC50 value of 0.39 μM .
|
-
-
- HY-146163
-
|
Topoisomerase
Apoptosis
|
Cancer
|
Topoisomerase II inhibitor 7 (compound 3a) is a potent inhibitor of topoisomerase II alpha subtype, with an IC50 of 3.19 μM. Topoisomerase II inhibitor 7 can induce cell cycle arrest and apoptosis .
|
-
-
- HY-168003
-
|
ADAMTS
|
Cardiovascular Disease
|
ADAMTS7-IN-1 (Compound 3a) is an effective and selective inhibitor of ADAMTS7 with a Ki value of 9 nM. ADAMTS7-IN-1 can be used in the research of atherosclerosis .
|
-
-
- HY-115981
-
|
HCV Protease
|
Infection
|
NS5A-IN-2 (Compound 33) is a potent inhibitor of NS5A. NS5A-IN-2 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability . NS5A-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-10493
-
GS-9350
|
Cytochrome P450
HIV
|
Infection
Cancer
|
Cobicistat is a potent and selective inhibitor of cytochrome P450 3A (CYP3A) enzymes with IC50s of 30-285 nM. Cobicistat is a pharmacokinetic enhancer which increases the overall absorption of several HIV medications.
|
-
-
- HY-17464S
-
-
-
- HY-17464S1
-
-
-
- HY-17464R
-
|
Phosphodiesterase (PDE)
Autophagy
|
Cardiovascular Disease
Cancer
|
Cilostazol (Standard) is the analytical standard of Cilostazol. This product is intended for research and analytical applications. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM .
|
-
-
- HY-N6748
-
-
-
- HY-148284
-
|
Drug Derivative
|
Cancer
|
Berbamine acetate (Compound 3a) is the derivative of Berbamine (HY-N0714). Berbamine acetate exhibits antitumor activity, inhibits growth of Imatinib (HY-15463)-resistant K562 leukemia cells, with IC50 of 6.6 μM .
|
-
-
- HY-173203
-
|
CDK
|
Cancer
|
CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. CDK2-IN-43 can be used in the research of the anti-cancer field .
|
-
-
- HY-133086
-
|
5-HT Receptor
nAChR
|
Neurological Disease
Cancer
|
Hydrodolasetron is a metabolite of Dolasetron (HY-B0750). Hydrodolasetron is more potent than Dolasetron in inhibiting nAChR. Hydrodolasetron is a 5-HT(3A)R blocker with an IC50 of 0.29 nM. Hydrodolasetron has antiemetic activity .
|
-
-
- HY-W028690
-
DNMDP
3 Publications Verification
|
Phosphodiesterase (PDE)
|
Cancer
|
DNMDP, a phosphodiesterase 3A (PDE3A) inhibitor, is a potent and selective cancer cell cytotoxic agent. DNMDP binding to PDE3A promotes an interaction between PDE3A and Schlafen 12 (SLFN12). DNMDP shows clear cell-selective cytotoxicity .
|
-
-
- HY-151445
-
|
DNA Methyltransferase
Virus Protease
Flavivirus
|
Infection
|
ZIKV-IN-2 (compound 3a) is a potent ZIKV NS5 methyl transferase (MTase) inhibitor with an IC50 value of 38.86 μM. ZIKV-IN-2 inhibits ZIKV replication and infection. ZIKV-IN-2 can be used in research of Zika virus (ZIKV) .
|
-
-
- HY-17464S2
-
-
-
- HY-17464S3
-
OPC 13013-d6
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
Cancer
|
Cilostazol-d6 (OPC 13013-d6) is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM .
|
-
-
- HY-126144
-
|
GSK-3
|
Metabolic Disease
Cancer
|
GSK-3β inhibitor 1 (compound 3a) inhibits GSK-3β with an IC50 of 4.19 nM. GSK-3β inhibitor 1 demonstrates high antidiabetic efficacy in obese Streptozotocin (HY-13753)-treated rats .
|
-
-
- HY-W009689
-
|
Parasite
|
Infection
|
TbPTR1 inhibitor 2 (Compound 3a) is a PTR1 enzyme inhibitor, with IC50s of 34.2 and 32.9 μM for TbPTR1 and LmPTR1. TbPTR1 inhibitor 2 has anti-parasitic activity against T. brucei (IC50: 34.2 μM) .
|
-
-
- HY-115982
-
|
HCV Protease
|
Infection
|
NS5A-IN-3 (Compound 15) is a potent inhibitor of NS5A. NS5A-IN-3 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability. NS5A-IN-3 exhibits a higher resistance barrier than daclatasvir against genotype 1b . NS5A-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-159486
-
|
Succinate Dehydrogenase
Fungal
|
Infection
|
SDH-IN-18 (Compound 3a) is an inhibitor for succinate dehydrogenase (SDH) with an IC50 of 8.70 mg/L. SDH-IN-18 destroys fungal morphology and reproduction, exhibits antifungal activity against Rhizoctonia solani and Sclerotinia sclerotiorum with EC50 of 0.48 and 1.4 mg/L .
|
-
-
- HY-10493R
-
GS-9350 (Standard)
|
Reference Standards
Cytochrome P450
HIV
|
Infection
Cancer
|
Cobicistat (Standard) is the analytical standard of Cobicistat. This product is intended for research and analytical applications. Cobicistat is a potent and selective inhibitor of cytochrome P450 3A (CYP3A) enzymes with IC50s of 30-285 nM. Cobicistat is a pharmacokinetic enhancer which increases the overall absorption of several HIV medications.
|
-
-
- HY-169055
-
|
Virus Protease
|
Infection
Inflammation/Immunology
|
SARS-CoV-2 Mpro-IN-25 (Compound 3a) is a SARS-CoV-2 protease inhibitor with an IC50 value of 0.26 μM. SARS-CoV-2 Mpro-IN-25 exhibits antiviral activity and can be used in pneumonia-related research .
|
-
-
- HY-P990228
-
|
Interleukin Related
|
Others
|
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-10R/CD210.
|
-
-
- HY-10568
-
|
Phosphodiesterase (PDE)
|
Metabolic Disease
|
TC-E 5005 is a potent and selective PDE10A inhibitor with IC50 values of 7.28, 239, 779, 919, 3,100, and 3,700 nM for PDE10A, 2A, 11A, 5A, 7B and 3A, respectively. TC-E 5005 inhibits adrenergic and neurogenic smooth muscle contractions in the human prostate .
|
-
-
- HY-N12209
-
|
Others
|
Cancer
|
Neohelmanthicin A (compound 3A) is a phenylpropanoid compound with antitumor activity. The IC50s of Neohelmanthicin A for inhibiting leukemia cell line EL4, breast cancer cell line S180 and breast cancer cell line MCF7 are 0.13 μM, 7 μM and 23 μM respectively .
|
-
-
- HY-147885
-
|
HCV
|
Infection
|
HCV-IN-41 (compound 4) is a highly potent hepatitis C virus (HCV) inhibitor with an EC50 value of 0.006762 nM, 5.183 nM, 1.365 nM and 142.2 nM for HCV genotype 1b, 2a, 3a and 4a, respectively. HCV-IN-41 reduces HCV RNA replication .
|
-
-
- HY-120187
-
|
Others
|
Others
|
DDCPPB-Glu (compound 3a) is a compound with anti-tumor activity, which has the activity of inhibiting tumor cell growth and prolonging survival. DDCPPB-Glu has growth inhibition effect on various tumor cell lines, can increase the survival time of leukemia mice, and has inhibitory effect on tumors such as colon cancer and lung cancer.
|
-
-
- HY-155610
-
|
VEGFR
|
Cancer
|
VEGFR-2-IN-32 (Comp 3a) is an inhibitor of VEGFR-2 with an IC50 of 8.93 nM. VEGFR-2-IN-32 has cytotoxic activity against PC-3 cells with an IC50 of 1.22 μM. VEGFR-2-IN-32 can be used for anti-prostate cancer research .
|
-
-
- HY-10493S
-
GS-9350-d8
|
Isotope-Labeled Compounds
HIV
Cytochrome P450
|
Infection
|
Cobicistat-d8 (GS-9350-d8) is a deuterated version of Cobicistat (HY-10493). Cobicistat is a potent and selective inhibitor of cytochrome P450 3A (CYP3A) with IC50 values of 30-285 nM. Cobicistat is a pharmacokinetic enhancer that enhances the absorption of anti-HIV active molecules .
|
-
-
- HY-161839
-
|
Aldose Reductase
|
Cancer
|
AKR1C2/3-IN-1 (compound 3a) is a potent AKR1C2 and AKR1C3 inhibitor with IC50 values of 90, 50 nM, respectively. AKR1C2/3-IN-1 can be used as a radiation sensitizer and as a potentiator of chemotherapy cytotoxicity .
|
-
-
- HY-155979
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 3CLpro-IN-16 (Compound 3a) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 2.124 μM). SARS-CoV-2 3CLpro-IN-16 binds to the active site and forms a covalent bond with Cys145 of 3CLpro .
|
-
-
- HY-142686
-
|
SGK
|
Inflammation/Immunology
|
SGK1-IN-3 (compound 3a) is a potent and orally active inhibitor of SGK1. The serine/threonine kinase SGK1 is an activator of the β-catenin pathway and a powerful stimulator of cartilage degradation that is found to be upregulated under genomic control in diseased osteoarthritic cartilage. SGK1-IN-3 has the potential for the research of osteoarthritis .
|
-
-
- HY-142686A
-
|
SGK
|
Inflammation/Immunology
|
SGK1-IN-3 hydrochloride (compound 3a) is a potent and orally active inhibitor of SGK1. The serine/threonine kinase SGK1 is an activator of the β-catenin pathway and a powerful stimulator of cartilage degradation that is found to be upregulated under genomic control in diseased osteoarthritic cartilage. SGK1-IN-3 hydrochloride has the potential for the research of osteoarthritis .
|
-
- HY-169622
-
|
RAD51
|
Others
|
RAD51-IN-9 (Compound 3a) is a RAD51 inhibitor that can inhibit the binding of RAD51 to ssDNA with an IC50 of 17.85 μM. RAD51-IN-9 has a LD50 against HEK293 cells of 40.21 μM. RAD51-IN-9 can sensitize cells to Mitomycin C (HY-13316) .
|
-
- HY-124191
-
PPI-668 hydrochloride
|
HCV
|
Infection
|
Ravidasvir hydrochloride (PPI-668 hydrochloride) is a pan-genotypic inhibitor for hepatitis C virus (HCV) NS5A protein. Ravidasvir hydrochloride inhibits the replication of HCV, with EC50 of 0.12, 0.01 and 1.14 nM, for HCV gt-1a, gt-1b, and gt-3a replicons, respectively. Ravidasvir hydrochloride exhibits good pharmacokinetic characters in rats .
|
-
- HY-149305
-
-
- HY-168559
-
|
EGFR
Apoptosis
|
Cancer
|
EGFR-IN-131 (compound 3a) is a potent and cross the blood-brain barrier EGFR inhibitor with an IC50 value of 272.9 nM. EGFR-IN-131 shows antiproliferative activity. EGFR-IN-131 induces apoptosis and cell cycle arrest at G0/G1 phase. EGFR-IN-131 decreases the protein expression of p-EGFR .
|
-
- HY-19840
-
GS-9857
|
HCV Protease
|
Infection
Cancer
|
Voxilaprevir (GS-9857) is a noncovalent, reversible inhibitor of HCV NS3/4A protease inhibitor (PI) with pangenotypic antiviral activity . Voxilaprevir inhibits genotype 1b and 3a wild-type NS3 proteases with Ki values of 0.038 nM and 0.066 nM, respectively . Voxilaprevir is an orally active direct-acting antiviral agent (DAA) and can be used for HCV infection research .
|
-
- HY-126144A
-
|
GSK-3
|
Metabolic Disease
|
(E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC50 of 4.9 nM .
|
-
- HY-131986
-
|
TRP Channel
|
Neurological Disease
Inflammation/Immunology
|
LASSBio-1135 (Compound 3a) is an orally active TRPV1 antagonist. LASSBio-1135 is an anti-inflammatory and analgesic compound. LASSBio-1135 inhibits moderately the human PGHS-2 enzyme activity (IC50 = 18.5 μM). LASSBio-1135 reverts the Capsaicin (HY-10448)-induced thermal hyperalgesia and reduces the carrageenan-induced rat paw edem .
|
-
- HY-133180
-
|
Wnt
β-catenin
|
Metabolic Disease
|
YW1128 (compound 3a) is a potent Wnt/β-Catenin inhibitor. YW1128 induces the proteasome degradation of β-catenin and subsequent inhibits the Wnt/β-catenin signaling in cells. YW1128 significantly decreases hepatic lipid accumulation. YW1128 improves glucose tolerance of high fat diet-fed mice without noticeable toxicity. YW1128 down regulates the genes involved in the glucose and fatty acid anabolism .
|
-
- HY-15745A
-
|
HCV
|
Infection
|
PSI-7409 tetrasodium is an active 5'-triphosphate metabolite of sofosbuvir (PSI-7977), inhibiting HCV NS5B polymerases, with IC50s of 1.6, 2.8, 0.7 and 2.6 μM for GT 1b_Con1, GT 2a_JFH1, GT 3a, and GT 4a NS5B polymerases, respectively.
|
-
- HY-15335
-
|
MDM-2/p53
E1/E2/E3 Enzyme
|
Cancer
|
Nutlin-3b, the inactive form of Nutlin-3 (HY-50696), is a p53/MDM2 inhibitor with an IC50 of 13.6 μM. Nutlin-3b is 150 times less potent in binding to MDM2 than Nutlin-3a (HY-10029). Nutlin-3b is promising for research of cancers .
|
-
- HY-A0165
-
|
Phosphodiesterase (PDE)
|
Neurological Disease
|
Tofisopam, a 2,3-benzodiazepine compound, is an orally active anxiolytic agent. Tofisopam can inhibit phosphodiesterase PDE isoenzyme activity, withIC50 values of 2.11 μM, 1.98 μM, 0.42 μM, and 0.92 μM for PDE-2A3, PDE-3A, PDE-4A1, and PDE-10A1, respectively. Tofisopam can be used for the study of anxiety .
|
-
- HY-117026
-
|
Cytochrome P450
|
Metabolic Disease
Inflammation/Immunology
|
LKY-047, a Decursin derivative, is a potent and selective reversible competitive cytochrome P45022J2 (CYP2J2) inhibitor with an IC50 of 1.7 μM. LKY-047 is inactive against other human P450s, such as CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A .
|
-
- HY-12594
-
ABT-450; Veruprevir
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .
|
-
- HY-131905S
-
|
Isotope-Labeled Compounds
HCV Protease
HCV
|
Infection
Inflammation/Immunology
Cancer
|
BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC50s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .
|
-
- HY-12594A
-
ABT-450 dihydrate; Veruprevir dihydrate
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor) .
|
-
- HY-125182
-
|
Cyclophilin
HCV
|
Infection
|
SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC50 of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC50s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction .
|
-
- HY-12594R
-
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
Paritaprevir (Standard) is the analytical standard of Paritaprevir. This product is intended for research and analytical applications. Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .
|
-
- HY-A0165R
-
|
Phosphodiesterase (PDE)
Reference Standards
|
Neurological Disease
|
Tofisopam (Standard) is the analytical standard of Tofisopam (HY-A0165). This product is intended for research and analytical applications. Tofisopam, a 2,3-benzodiazepine compound, is an orally active anxiolytic agent. Tofisopam can inhibit phosphodiesterase PDE isoenzyme activity, withIC50 values of 2.11 μM, 1.98 μM, 0.42 μM, and 0.92 μM for PDE-2A3, PDE-3A, PDE-4A1, and PDE-10A1, respectively. Tofisopam can be used for the study of anxiety .
|
-
- HY-146253
-
|
CDK
Apoptosis
Bcl-2 Family
Caspase
|
Cancer
|
CDK1/2/4-IN-1 (compound 3a) is a potent CDK inhibitor with IC50 values of 1.47, 0.78 and 0.87 μM for CDK1, CDK2 and CDK4, respectively. CDK1/2/4-IN-1 arrests cell cycle at G2/M phase and induces apoptosis. CDK1/2/4-IN-1 elevates Bax, caspase-3, P53 levels and decreases Bcl-2 level. CDK1/2/4-IN-1 can be used for cancer research .
|
-
- HY-10238
-
ITMN-191; R7227; RO5190591; RG7227
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC50 of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC50 higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC50s=0.2-0.4 nM) as well as 2b and 3a (IC50s=1.6, 3.5 nM) . Danoprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 0.05 μM .
|
-
- HY-146294
-
|
COX
|
Inflammation/Immunology
|
COX-2/5-LOX-IN-1 (compound 3a) is a potent and dual inhibitor of COX-2/5-LOX. COX-2/5-LOX-IN-1 is a benzothiophen-2-yl pyrazole carboxylic acid derivative. COX-2/5-LOX-IN-1 shows the most potent analgesic and anti-inflammatory activities surpassing that of Celecoxib and Indomethacin. COX-2/5-LOX-IN-1 shows potent COX-1, COX-2 and 5-LOX inhibitory activity with IC50s of 12.13, 0.4 and 4.96 μM, respectively .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10802
-
|
Enterovirus
Virus Protease
|
Infection
|
ER-DRI is a potent peptide inhibitor that tagets EV-A71. ER-DRI directly bounds to 3A and specifically abrogates viral suppressor of RNAi activity, which unlocked the antiviral RNAi response that is suppressed by 3A. ER-DRI also potently inhibits another enterovirus, Coxsackievirus-A16, dependently of RNAi .
|
Cat. No. |
Product Name |
Target |
Research Area |
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-17464S
-
|
Cilostazol-d11 is the deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM .
|
-
-
- HY-17464S1
-
|
Cilostazol-d4 is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM .
|
-
-
- HY-17464S2
-
|
Cilostazol-d2 (OPC 13013-d2) is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM .
|
-
-
- HY-17464S3
-
|
Cilostazol-d6 (OPC 13013-d6) is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM .
|
-
-
- HY-10493S
-
|
Cobicistat-d8 (GS-9350-d8) is a deuterated version of Cobicistat (HY-10493). Cobicistat is a potent and selective inhibitor of cytochrome P450 3A (CYP3A) with IC50 values of 30-285 nM. Cobicistat is a pharmacokinetic enhancer that enhances the absorption of anti-HIV active molecules .
|
-
-
- HY-131905S
-
|
BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC50s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: